Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components

N/AActive Not RecruitingNCT02285842

MicroPort Orthopedics Inc.143 enrolled

Overview

MicroPort Orthopedics (MPO) is conducting this PMCF study to evaluate the safety and efficacy of its THA and resurfacing components marketed in the EU. These types of studies are required by regulatory authorities for all THA and resurfacing devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with MEDDEV 2.12/2 rev 2.

MicroPort Orthopedics Inc. (MPO) currently markets several total hip arthroplasty (THA) and resurfacing components throughout the world, including the European Union (EU). As part of the process for gaining approval to market in the EU, MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of these components. The objectives of this study are to evaluate component survivorship, total functional outcome scores, and radiographic outcomes of implanted subjects at out to 10 years follow-up.

Study Type

OBSERVATIONAL

Enrollment

143

Conditions

Joint Disease

Interventions

Primary hip resurfacing deviceDEVICE

CONSERVE® Press-Fit Femoral Components

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has undergone primary hip resurfacing for any of the following: * Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia; * Inflammatory degenerative joint disease such as rheumatoid arthritis; or * Correction of functional deformity * Subject is implanted with the specified combination of components * Subject is willing and able to complete required study visits or assessments Exclusion Criteria: * Subjects skeletally immature (less than 21 years of age) at time of primary resurfacing surgery * Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol * Subjects unwilling to sign the Informed Consent document * Subjects with substance abuse issues * Subjects who are incarcerated or have pending incarceration

Locations (1)

Ottawa Hospital

Ottawa, Ontario, Canada

Outcomes

Primary Outcomes

Component Survivorship

The primary objective of this study is to estimate survivorship of all components at specified intervals out to 10 years follow-up.

Time frame: 10 years post-operative

Secondary Outcomes

Patient functional outcomes

To characterize total functional scores, as assessed by HOOS and EQ-5D-3L scores

Time frame: Screening (First Available), 2-5 years, 5-7 years, and 10 years

Component alignment

To evaluate component alignment (neck shaft angle, stem shaft angle, and cup inclination) and the presence of radiolucencies surrounding implanted components

Time frame: Screening (First Available), 2-5 years, 5-7 years, and 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.